Invivyd Upsizes DECLARATION Trial, Aims for Late 2026 COVID Antibody Data

Event summary

  • Invivyd completed enrollment in its Phase 3 DECLARATION trial for VYD2311, a monoclonal antibody to prevent COVID-19, adding ~500 participants after a sample size re-estimation.
  • The trial evaluates both single-dose and monthly dosing regimens of VYD2311 via intramuscular injection against placebo.
  • Top-line results are expected in late Q3 2026, with rapid enrollment suggesting strong interest in monoclonal antibody protection.
  • VYD2311 leverages Invivyd’s proprietary technology platform, designed to neutralize contemporary SARS-CoV-2 variants.

The big picture

Invivyd’s upsized DECLARATION trial reflects the ongoing demand for prophylactic COVID-19 solutions, particularly as variants continue to emerge. The company’s focus on intramuscular administration and flexible dosing aligns with broader industry trends toward patient-friendly, adaptable treatments. Success hinges on demonstrating sustained efficacy and securing regulatory approval in a market where vaccine fatigue and variant evolution pose challenges.

What we're watching

Regulatory Pathway
How Invivyd navigates the FDA’s Biologics License Application (BLA) process for VYD2311, given the evolving COVID-19 landscape.
Market Differentiation
Whether VYD2311’s flexible dosing regimen can position it as a preferred option for at-risk populations seeking periodic protection.
Clinical Efficacy
The pace at which VYD2311 demonstrates long-term protection beyond the initial three-month dosing interval.